Literature DB >> 11960385

Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived.

Takashi Ueki1, Kimberly M Walter, Halcyon Skinner, Elizabeth Jaffee, Ralph H Hruban, Michael Goggins.   

Abstract

A higher prevalence of epigenetic inactivation of tumor suppressor genes has been reported in cancer cell line populations compared to primary cancer populations. Cancer-related genes are commonly methylated in cancer cell lines but it is not known the extent to which tumor suppressor genes may be artificially methylated in vitro. We therefore examined 10 pancreatic cancer cell lines and corresponding primary tumors for aberrant DNA methylation of promoter CpG islands of eight genes and seven CpG islands. Using methylation-specific PCR (MSP), methylation was not detected at any of the 15 CpG islands in 15 normal pancreata or in an immortalized normal pancreatic duct epithelial (HPDE) cell line. Of 150 loci examined, 49 loci were methylated in both primary carcinomas and their corresponding cell lines, 95 loci were not methylated in either cell lines or their corresponding primary carcinomas. There were four loci methylated only in cell lines while another two loci were methylated only in primary carcinomas. Overall, the methylation status of primary carcinomas and their cell lines were concordant in 96% of cases (144 of 150) (J statistic; J=0.92, P<0.0001). We conclude that most of the DNA methylation of tumor suppressor genes observed in cancer cell lines is present in the primary carcinomas from which they were derived.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960385     DOI: 10.1038/sj.onc.1205275

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

Review 1.  Identifying molecular markers for the early detection of pancreatic neoplasia.

Authors:  Michael Goggins
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

2.  Genetics and pathology of pancreatic cancer.

Authors:  Jordan M Winter; Anirban Maitra; Charles J Yeo
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

Review 3.  Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have.

Authors:  Marta Herreros-Villanueva; Luis Bujanda
Journal:  Ann Transl Med       Date:  2016-04

Review 4.  Pancreatic cancer screening.

Authors:  Eun Ji Shin; Marcia Irene Canto
Journal:  Gastroenterol Clin North Am       Date:  2012-01-05       Impact factor: 3.806

5.  Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer.

Authors:  Noriomi Matsumura; Zhiqing Huang; Seiichi Mori; Tsukasa Baba; Shingo Fujii; Ikuo Konishi; Edwin S Iversen; Andrew Berchuck; Susan K Murphy
Journal:  Genome Res       Date:  2010-12-14       Impact factor: 9.043

6.  CpG island methylation profile of pancreatic intraepithelial neoplasia.

Authors:  Norihiro Sato; Noriyoshi Fukushima; Ralph H Hruban; Michael Goggins
Journal:  Mod Pathol       Date:  2007-12-21       Impact factor: 7.842

Review 7.  Strategies for early detection of resectable pancreatic cancer.

Authors:  Keiichi Okano; Yasuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 8.  Breast cancer epigenetics: normal human mammary epithelial cells as a model system.

Authors:  Rebecca A Hinshelwood; Susan J Clark
Journal:  J Mol Med (Berl)       Date:  2008-08-21       Impact factor: 4.599

Review 9.  Molecular detection of pancreatic neoplasia: Current status and future promise.

Authors:  Shounak Majumder; Suresh T Chari; David A Ahlquist
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

10.  Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.

Authors:  Sonja Röhrs; Wilhelm G Dirks; Claus Meyer; Rolf Marschalek; Michaela Scherr; Robert Slany; Andrew Wallace; Hans G Drexler; Hilmar Quentmeier
Journal:  Mol Cancer       Date:  2009-10-16       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.